1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Atopic Dermatitis (AD) Treatment Market
2.2. Global Atopic Dermatitis (AD) Treatment Market, By Drug, 2023 (US$ Million)
2.3. Global Atopic Dermatitis (AD) Treatment Market, By Geography, 2023 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2023

3. Atopic Dermatitis (AD) Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Atopic Dermatitis (AD) Treatment Market Vendors
3.2. Strategies Adopted by Atopic Dermatitis (AD) Treatment Market Vendors
3.3. Key Industry Strategies
4. Atopic Dermatitis (AD) Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Atopic Dermatitis (AD) Treatment Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Atopic Dermatitis (AD) Treatment Market: By Drug, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Anti-inflammatory agents
5.3.1.1. Corticosteroids
5.3.1.2. Calcineurin Inhibitors
5.3.2. Antihistamines
5.3.3. Immunomodulators
5.3.4. Interleukin Inhibitors
5.3.5. Topical Phosphodiesterase-4 (PDE-4) Inhibitors
5.3.6. Antiviral agents
5.3.7. Antibiotics


6. North America Atopic Dermatitis (AD) Treatment Market, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Atopic Dermatitis (AD) Treatment Market: By Drug, 2022-2032, USD (Million)
6.3.Atopic Dermatitis (AD) Treatment Market: By Region, 2022-2032, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2022-2032, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2022-2032, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2022-2032, USD (Million)

7. UK and European Union Atopic Dermatitis (AD) Treatment Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Atopic Dermatitis (AD) Treatment Market: By Drug, 2022-2032, USD (Million)
7.3.Atopic Dermatitis (AD) Treatment Market: By Region, 2022-2032, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2022-2032, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2022-2032, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2022-2032, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2022-2032, USD (Million)
7.3.1.5. France
7.3.1.5.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2022-2032, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2022-2032, USD (Million)

8. Asia Pacific Atopic Dermatitis (AD) Treatment Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Atopic Dermatitis (AD) Treatment Market: By Drug, 2022-2032, USD (Million)
8.3.Atopic Dermatitis (AD) Treatment Market: By Region, 2022-2032, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2022-2032, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2022-2032, USD (Million)
8.3.1.3. India
8.3.1.3.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2022-2032, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2022-2032, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2022-2032, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2022-2032, USD (Million)

9. Latin America Atopic Dermatitis (AD) Treatment Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Atopic Dermatitis (AD) Treatment Market: By Drug, 2022-2032, USD (Million)
9.3.Atopic Dermatitis (AD) Treatment Market: By Region, 2022-2032, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2022-2032, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2022-2032, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2022-2032, USD (Million)

10. Middle East and Africa Atopic Dermatitis (AD) Treatment Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Atopic Dermatitis (AD) Treatment Market: By Drug, 2022-2032, USD (Million)
10.3.Atopic Dermatitis (AD) Treatment Market: By Region, 2022-2032, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2022-2032, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2022-2032, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Atopic Dermatitis (AD) Treatment Market: By Drug, 2022-2032, USD (Million)

11. Company Profile
11.1. AbbieVie Inc.
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Encore Dermatology Inc.
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. F. Hoffmann-La Roche AG
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Glaxosmithkline plc.
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. LEO Pharma A/S
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Medimmune LLC. (Astrazeneca)
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Novartis AG
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Pfizer Inc.
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Regeneron Pharmaceuticals Inc.
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Sanofi S.A.
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Valeant Pharmaceuticals Inc.
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives